SCHEMBL17898309

SCHEMBL17898309

Oc1nc(Oc2ccc(OC3CCCC3)cc2)nc2cnccc12

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 10/20 0.46
▸ HRH3 Q9Y5N1 2/20 0.44
▸ ROCK1 Q13464 1/20 0.37
▸ IKBKB O14920 1/20 0.36
▸ LATS1 O95835 2/20 0.36
▸ LATS2 Q9NRM7 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.35
▸ KDM4A O75164 2/20 0.35
▸ KDM5C P41229 2/20 0.35
▸ KDM4D Q6B0I6 2/20 0.35
▸ GPR6 P46095 1/20 0.34
▸ CACNA1B Q00975 1/20 0.34
▸ NAMPT P43490 1/20 0.34
▸ PRKCZ Q05513 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17615615 0.92 KDM4C (0.46) KDM4CHRH3
SCHEMBL17517203 0.87 KDM4C (0.52) KDM4CHRH3ROCK1LATS1LATS2
SCHEMBL17615602 0.87 KDM4C (0.48) KDM4C
SCHEMBL17898307 0.84 HRH3 (0.44) KDM4CHRH3GPR6NAMPT
SCHEMBL17898311 0.82 KDM4C (0.49) KDM4CKDM4EKDM4AKDM5CKDM4D
SCHEMBL17898304 0.81 KDM4C (0.45) KDM4C
SCHEMBL17615756 0.80 KDM4C (0.44) KDM4C
SCHEMBL17503677 0.79 ALDH1A1 (0.50) KDM4CLATS1KDM4EKDM4AKDM5C
SCHEMBL16096164 0.79 KDM4C (0.53) KDM4CKDM4EKDM4AKDM5CKDM4D
SCHEMBL16095235 0.79 HTT (0.40) KDM4CLATS1LATS2KDM4EKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3430008-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2022-05-18 — — EP disclosed
US-10208039-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-02-19 — — US disclosed
US-10202381-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-02-12 — — US disclosed
US-10030017-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-24 — — US disclosed
US-10030017-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-24 — — US disclosed
US-20180162857-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-06-14 — — US disclosed
US-20180162857-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-06-14 — — US disclosed
WO-2017161012-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2017-09-21 — — WO disclosed
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-07-07 — — US disclosed
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5C, KDM1A KDM4C 9/4885HRH3 437/4885ROCK1 653/4885
US-10030017-B2 Histone demethylase inhibitors KDM1B, KDM5C, KDM1A KDM4C 9/4885HRH3 437/4885ROCK1 653/4885
US-20180162857-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5C, KDM1A KDM4C 9/4885HRH3 437/4885ROCK1 653/4885
US-10202381-B2 Histone demethylase inhibitors KDM1B, KDM5C, KDM1A KDM4C 9/4885HRH3 437/4885ROCK1 653/4885
US-10208039-B2 Histone demethylase inhibitors KDM1B, KDM5C, KDM1A KDM4C 9/4885HRH3 437/4885ROCK1 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback